Publications
Opportunities to Increase Efficiency in Healthcare
1 October 2020
Substantial economic resources are devoted to healthcare across Europe, but there is evidence that a large proportion of these resources are of limited benefit to patients and society.
How do we Measure the “Value” in Value-Based care?
1 October 2020
Determining and defining value in health care is a persistent challenge in every country. To some extent, what constitutes value depends on perspective, e.g. a pharmaceutical company…
The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
1 September 2020
Vaccines are widely regarded as one of the most important public health achievements of the last century. Health economists, however, have long highlighted the gaps between…
Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals
1 September 2020
In the focus on US drug prices, ICER has contributed thinking on determining when price aligns with patient benefits. Less debated is whether insurance coverage provides…
Realising the Broader Value of Vaccines in the UK
8 January 2020
Many health technology assessment (HTA) agencies limit their assessment of vaccines to individual health benefits and the costs associated with vaccine administration and the disease avoided.…
The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective
1 August 2020
Most value assessments of vaccination programs are carried out by taking the perspective of the health system. To stimulate the debate concerning the broader value of vaccination beyond this perspective, this report quantifies the related return on investment to the UK government.
Incentives for R&D: Payment Options and Pricing Challenges
8 January 2020
The issue of rising prescription drug prices is a concern in every country. Dozens of policy initiatives and hundreds of research projects over last the fifty…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin,…
NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
7 January 2020
The National Institute of Health and Care Excellence (NICE) makes recommendations for the use of interventions including medicines in the National Health Service in England based…